Insider Transactions in Q3 2021 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,000
-26.33%
|
$70,000
$35.88 P/Share
|
|
Sep 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+37.84%
|
$2,000
$1.86 P/Share
|
|
Sep 07
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,600
-10.13%
|
$56,000
$35.0 P/Share
|
|
Sep 07
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,600
+9.2%
|
$11,200
$7.26 P/Share
|
|
Sep 07
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,200
-71.33%
|
$112,000
$35.25 P/Share
|
|
Sep 07
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+41.63%
|
$3,200
$1.86 P/Share
|
|
Sep 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.74%
|
$12,800
$32.34 P/Share
|
|
Sep 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.67%
|
$2,800
$7.26 P/Share
|
|
Aug 10
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-38.89%
|
$217,500
$29.97 P/Share
|
|
Aug 10
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+38.8%
|
$7,500
$1.11 P/Share
|
|
Aug 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-59.85%
|
$34,800
$29.87 P/Share
|
|
Aug 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+37.44%
|
$1,200
$1.86 P/Share
|
|
Aug 02
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.82%
|
$12,400
$31.21 P/Share
|
|
Aug 02
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.74%
|
$2,800
$7.26 P/Share
|
|
Jul 20
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-59.85%
|
$32,400
$27.0 P/Share
|
|
Jul 20
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+37.44%
|
$1,200
$1.86 P/Share
|
|
Jul 12
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-34.24%
|
$180,000
$24.3 P/Share
|
|
Jul 12
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+38.8%
|
$7,500
$1.11 P/Share
|
|
Jul 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.82%
|
$10,400
$26.76 P/Share
|
|
Jul 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.74%
|
$2,800
$7.26 P/Share
|